Drug Discovery World

FEBRUARY 28, 2024

CRISPR and brain cancer Meanwhile, elsewhere in the US, another exciting development – using CRISPR as a therapeutic approach – has possibilities for tackling brain cancer. Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers.

Development 64

Development Research Drugs Antibody 64

The Pharma Data

APRIL 11, 2023

The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

AUGUST 2, 2023

Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. 2022 was the first year on market for cell-based gene therapies Abecma (Idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) , which generated $388 million and $182 million, respectively. Both are anti-CD20 agents.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

APRIL 29, 2024

Scott Kobayashi, Senior Vice President of Sales, BioPhy: Kobayashi previously founded Delta Project Management, a life sciences consulting firm he sold to Versita in 2022, and held consulting roles with companies like Pfizer, Genentech, and Flour.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

MARCH 6, 2024

Guiding neurological drug discovery and development to success The 20 years since the Human Genome Project has seen transformational advances in the molecular understanding of cancers and rare genetic diseases, leading to genetically informed, personalised selection of therapies and massively improved outcomes for many patients.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

XTalks

SEPTEMBER 14, 2020

Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like. Addressing the Rapidly Evolving Vaccine Development Landscape.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

Drug Discovery World

NOVEMBER 30, 2023

Lonza’s integrated CMC strategy and timeline was presented, as well as case studies highlighting key approaches and technologies, including: vector design & integration, cell line selection, downstream process, analytical method and formulation development. kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 13, 2023

The track will be opened by chairperson remarks from Daniel Chen, MD, PhD, Founder, Engenuity Life Sciences, which will be followed by the track’s keynote presentation by Bent Jakobsen, PhD, FMedSci, CEO & Founder, Accession Therapeutics. It is called, ‘An unexpected future for immune oncology therapies?’

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . Hamish Ryder.

HR 52

HR Research Drugs Development 52

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Therapy Gene 130